Mackenzie Financial
CRL icon

Mackenzie Financial’s Charles River Laboratories CRL Stock Holding History

Mackenzie Financial’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Sell
594,800
-186,676
-24% -$34.6M 0.12% 152
2025
Q4 		$158M Sell
781,476
-213,911
-21% -$38.8M 0.19% 108
2025
Q3 		$156M Sell
995,387
-6,662
-0.7% -$1.06M 0.19% 112
2025
Q2 		$152M Sell
1,002,049
-902
-0.1% -$120K 0.2% 113
2025
Q1 		$151M Buy
1,002,951
+25,878
+3% +$4.34M 0.21% 113
2024
Q4 		$180M Buy
977,073
+5,805
+0.6% +$1.12M 0.25% 99
2024
Q3 		$191M Buy
971,268
+42,108
+5% +$8.75M 0.27% 96
2024
Q2 		$192M Sell
929,160
-2,637
-0.3% -$598K 0.29% 94
2024
Q1 		$252M Buy
931,797
+13,939
+2% +$3.33M 0.36% 73
2023
Q4 		$217M Sell
917,858
-5,791
-0.6% -$1.14M 0.33% 81
2023
Q3 		$177M Buy
923,649
+4,507
+0.5% +$925K 0.3% 87
2023
Q2 		$192M Buy
919,142
+53,032
+6% +$10.6M 0.29% 91
2023
Q1 		$175M Buy
866,110
+65,534
+8% +$14.9M 0.27% 91
2022
Q4 		$174M Buy
800,576
+89,751
+13% +$19.6M 0.29% 89
2022
Q3 		$140M Sell
710,825
-276,409
-28% -$59.7M 0.24% 100
2022
Q2 		$211M Buy
987,234
+131,020
+15% +$32M 0.34% 68
2022
Q1 		$243M Buy
856,214
+553,121
+182% +$171M 0.33% 73
2021
Q4 		$114M Sell
303,093
-3,820
-1% -$1.48M 0.15% 147
2021
Q3 		$127M Sell
306,913
-140,543
-31% -$58.4M 0.18% 139
2021
Q2 		$166M Buy
447,456
+185,667
+71% +$62M 0.23% 105
2021
Q1 		$75.9M Sell
261,789
-167,554
-39% -$46.6M 0.12% 169
2020
Q4 		$107M Buy
429,343
+60,774
+16% +$14.5M 0.23% 129
2020
Q3 		$83.5M Buy
368,569
+2,863
+0.8% +$594K 0.21% 134
2020
Q2 		$63.8M Buy
365,706
+104,445
+40% +$16.7M 0.17% 146
2020
Q1 		$33M Buy
261,261
+6,683
+3% +$1M 0.11% 184
2019
Q4 		$38.9M Buy
254,578
+69,400
+37% +$9.61M 0.1% 194
2019
Q3 		$24.5M Buy
185,178
+183,382
+10,211% +$24.6M 0.06% 223
2019
Q2 		$255K Sell
1,796
-27,388
-94% -$3.71M ﹤0.01% 990
2019
Q1 		$4.24M Buy
+29,184
New +$3.83M 0.01% 578
2018
Q2 		– Sell
-719,731
Closed -$76.8M – 1012
2018
Q1 		$76.8M Sell
719,731
-351,447
-33% -$37.9M 0.2% 115
2017
Q4 		$117M Buy
1,071,178
+142,382
+15% +$15.5M 0.28% 71
2017
Q3 		$100M Buy
928,796
+417,739
+82% +$42.9M 0.54% 41
2017
Q2 		$51.7M Buy
511,057
+49,557
+11% +$4.56M 0.29% 100
2017
Q1 		$41.5M Hold
461,500
– – 0.24% 115
2016
Q4 		$35.2M Buy
461,500
+420,675
+1,030% +$31.9M 0.21% 131
2016
Q3 		$3.4M Buy
40,825
+4,995
+14% +$419K 0.02% 286
2016
Q2 		$2.95M Buy
+35,830
New +$2.95M 0.02% 376

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mackenzie Financial's CRL Position: Q1 2026 in Review

Mackenzie Financial reduced its Charles River Laboratories (CRL) stake by 24% in Q1 2026, selling an estimated $34.6M and leaving 594,800 shares worth $103M. The position accounts for 0.12% of the portfolio, ranked #152.

Mackenzie Financial first reported a position in CRL in Q2 2016 and has held it in 37 quarters since. The position peaked at $252M in Q1 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Mackenzie Financial held 594,800 shares of Charles River Laboratories worth $103M as of Q1 2026.
  • Mackenzie Financial sold 186,676 Charles River Laboratories shares in Q1 2026, an estimated $34.6M.
  • Charles River Laboratories made up 0.12% of Mackenzie Financial's portfolio in Q1 2026, its #152 holding.
  • Mackenzie Financial first reported a position in Charles River Laboratories in Q2 2016 and has held it in 37 quarters since.
  • Mackenzie Financial's Charles River Laboratories position peaked at $252M in Q1 2024.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.